Generian, Astellas to develop molecules for undruggable therapeutic targets
Generian Pharmaceuticals has signed a collaboration and exclusive license agreement with Astellas Pharma’s wholly owned subsidiary Mitobridge for the research and development of new small molecules for undruggable therapeutic targets.